PBLS · Parabilis Medicines, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-06-30 | USD 5,710,000 | 10-Q filed 2026-08-13 |
| Current finance lease liabilities | 2026-06-30 | USD 669,000 | 10-Q filed 2026-08-13 |
| Current long-term debt and lease obligations | 2026-06-30 | USD 726,000 | 10-Q filed 2026-08-13 |
| Current operating lease liabilities | 2026-06-30 | USD 7,592,000 | 10-Q filed 2026-08-13 |
| Current portion of long-term debt | 2026-06-30 | USD 5,710,000 | 10-Q filed 2026-08-13 |
| Noncurrent finance lease liabilities | 2026-06-30 | USD 1,128,000 | 10-Q filed 2026-08-13 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 700,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 32,413,000 | 10-Q filed 2026-08-13 |
| Short-term borrowings | 2026-06-30 | USD 5,000,000 | 10-Q filed 2026-08-13 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 197 similar-size Biotechnology companies (of 532 listed).